References

  1. Graves R. Newly observed affection of the thyroid gland in females (Clinical lectures). London Medical and Surgical Journal (Renshaw). 1835; 7(2): 516-7.

  2. Parry CH. Collections from the unpublished medical writings of the late Caleb Hillier Parry. London: Underwoods. 1825; 1: 2.

  3. Legge RI. Parry and Parry's disease. Res Medica. 1961; 2(4):33-7.

  4. Ogbera AO, Kuku SF. Epidemiology of thyroid diseases in Africa. Indian J Endocrinol Metab. 2011 Jul;15(Suppl 2):S82-8. PubMed | Google Scholar

  5. Ogbera A, Okosieme O. Thyroid diseases in Africa: epidemiology and management challenges. Thyroid International. 2014;1.

  6. Kalk WJ, Kalk J. Incidence and causes of hyperthyroidism in blacks. S Afr Med J. 1989 Feb 04;75(3):114-7. PubMed | Google Scholar

  7. Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994 Jun 16;330(24):1731-8. PubMed | Google Scholar

  8. Melmed S, Polonsky K, Larsen PR, Kronenberg H. Williams Textbook of Endocrinology. Philadelphia: Elsevier/Saunders. 2011.

  9. Werner SC, Ingbar SH, Braverman LE, Utiger RD. Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text. Philadelphia: Lippincott-Raven. 1996. Google Scholar

  10. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51. PubMed | Google Scholar

  11. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005 Aug;115(8):1972-83. PubMed | Google Scholar

  12. Bech K. Yersinia enterocolitica and thyroid autoimmunity. Autoimmunity. 1990;7(4):291-4. PubMed | Google Scholar

  13. Wolf MW, Misaki T, Bech K, Tvede M, Silva JE, Ingbar SH. Immunoglobulins of patients recovering from Yersinia enterocolitica infections exhibit Graves' disease-like activity in human thyroid membranes. Thyroid. 1991 Winter;1(4):315-20. PubMed | Google Scholar

  14. Davies TF, Greenberg D, Tomer Y. The genetics of the autoimmune thyroid diseases. Annales d'endocrinologie. 2003 Feb;64(1):28-30. PubMed | Google Scholar

  15. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003 Dec;24(6):802-35. PubMed | Google Scholar

  16. Brent GA. Clinical practice: Graves' disease. N Engl J Med. 2008 Jun 12;358(24):2594-605. PubMed | Google Scholar

  17. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marino M et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest. 2005 May;28(5):469-78. PubMed | Google Scholar

  18. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986: Results of an international survey. Acta endocrinologica Supplementum. 1987;285:3-23. PubMed | Google Scholar

  19. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129-35. PubMed | Google Scholar

  20. Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine: pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1996 Jan;37(1):185-92. PubMed | Google Scholar

  21. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013 Dec;9(12):724-34. PubMed | Google Scholar

  22. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf). 2008 Dec;69(6):943-50. PubMed | Google Scholar

  23. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7. PubMed | Google Scholar

  24. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998 Oct 15;129(8):632-5. PubMed | Google Scholar

  25. IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.

  26. Blahd WH, Hays MT. Graves' disease in the male: a review of 241 cases treated with an individually calculated dose of sodium iodide I 131. Arch Intern Med. 1972 Jan;129(1):33-40. PubMed | Google Scholar

  27. Onimode YA, Adedapo KS, Dairo MD. Ophthalmic manifestation as adverse factor for cure in radioiodine treatment of Graves' disease. Thyroid Res Pract. 2017; 14(1):18-21. Google Scholar

  28. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000 Mar;85(3):1038-42. PubMed | Google Scholar

  29. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997 Apr;7(2):163-76. PubMed | Google Scholar

  30. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011 Feb 10;364(6):542-50. PubMed | Google Scholar

  31. Wartofsky L. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America. Thyroid. 1997 Apr;7(2):213-6. PubMed | Google Scholar

  32. Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med. 1991 Mar;32(3):411-6. PubMed | Google Scholar

  33. Gomez N, Gomez JM, Orti A, Gavalda L, Villabona C, Leyes P et al. Transient hypothyroidism after iodine-131 therapy for Grave's disease. J Nucl Med. 1995 Sep;36(9):1539-42. PubMed | Google Scholar

  34. Sheehan MT, Doi SA. Transient Hypothyroidism after Radioiodine for Graves' disease: challenges in Interpreting thyroid Function Tests. Clin Med Res. 2016 Mar;14(1):40-5. PubMed | Google Scholar

  35. Gomez JM, Virgili N, Soler J, Fernandez M, Montana E. Transient hypothyroidism after iodine-131 treatment of Graves' disease. Thyroidology. 1989 Dec;1(3):149-52. PubMed | Google Scholar

  36. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med. 1996 Feb;37(2):228-32. PubMed | Google Scholar

  37. Berg G, Michanek A, Holmberg E, Nyström E. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. Journal of Internal Medicine. 1996;239(2):165-71. PubMed | Google Scholar

  38. Onimode YA, Ankrah A, Adedapo KS. Outcome of Radioiodine Therapy in a West African Population. World J Nucl Med. 2016 Jan-Apr;15(1):24-9. PubMed | Google Scholar